At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,401 enrolled
Drug / intervention
Enzalutamide +1 moredrug
Likely dose
Enzalutamide 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
In Brief
A Phase 3 clinical trial evaluating Enzalutamide and Placebo for Nonmetastatic Castration-Resistant Prostate Cancer and 2 related conditions. Completed, enrolled 1,401 participants across 397 sites in 32 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Italy, Malaysia, Netherlands, New Zealand, Poland, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedDec 2013
Primary CompletionJun 2017
Study CompletionNov 2025
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartOct 31, 2013
Primary CompletionJun 28, 2017
Study CompletionNov 28, 2025
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.6 years ago
Interventions
Enzalutamidedrug
160 mg by mouth once daily
Placebodrug
Sugar pill to mimic enzalutamide